SARASOTA, Fla., Sept. 12, 2005 (PRIMEZONE) -- DNAPrint(TM) genomics, Inc. (OTCBB:DNAG) announced today that president and chief executive officer Richard Gabriel will be presenting at the Medical Services Industry Conference sponsored by The New York Society of Security Analysts (NYSSA) on Wednesday, September 21, at The Harvard Club, 27 W. 44th St., in New York City, at 3:10 p.m. Eastern time.
Mr. Gabriel will provide an overview of DNAPrint genomics and its recent activities in the area of pharmacogenomics. Specifically, Mr. Gabriel's presentation will focus on how the company utilizes recent genomics and chemistry advances to develop next-generation drugs ("theranostics") maximizing efficacy and minimizing side effects by tailoring medications for specific individuals.
Mr. Gabriel's presentation will be available by means of a live Web cast that can be accessed on the company's Web site at www.dnaprint.com or at http://www.shareholder.com/DNAPrint/medialist.cfm. The Web cast, which includes a PowerPoint presentation, will also be archived.
Those wishing to attend Mr. Gabriel's presentation can register on The New York Society of Security Analysts, Inc., Web site at http://www.nyssa.org/eseries/source/Meetings/ibomeetregister.cfm?PRODUCT_MAJOR=MEDICAL05.
Conference attendees, including mutual and pension fund managers and analysts for the medical services industry, will have an opportunity to hear senior executives discuss the latest developments within the medical services industry sector.
The New York Society of Security Analysts (NYSSA), established in 1937, is a non-profit organization that provides investment professionals a forum for the exchange of ideas and information. Its goals are to inform and educate investors and to advance the professional competence of investment professionals including portfolio managers, security analysts, investment advisors, and others involved in the investment process.
DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology, and consumer genetic tests. DNAPrint's family of products for the law enforcement forensics, and consumer markets include DNAWITNESS(tm), RETINOME(tm), ANCESTRYbyDNA(tm), and EURO-DNA(tm).
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.